Innate Pharma S.A. Banner Image

Innate Pharma S.A.

  • Ticker IPHA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Innate Pharma S.A. Logo Image
  • 201-500 Employees
  • Based in Marseille, France
Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncologyMore product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
4.8 / 5.0 (64)

Innate Pharma S.A. reports have an aggregate usefulness score of 4.8 based on 64 reviews.

Innate Pharma S.A.

Most Recent Annual Report

Innate Pharma S.A.
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Innate Pharma S.A. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!